Xylitol Nasal Spray Prevents SARS-CoV-2 Infection

By Editorial Team -
The sophisticated American consumer has grown accustomed to the gold-standard for drug and health products—the prospective Randomized, double-blind, placebo-Controlled Trial (RCT). Operation Warp Speed (OWS) was supposed to be a churning mill of large RCT’s to help the nation understand what conclusively is effective in the prevention and treatment of COVID-19. Unfortunately, after three years, has delivered failed products (remdesivir, baricitinib, molnupiravir, COVID-19 vaccines) and small inconclusive trials of products that doctors have found effective in practice including off-target generic antivirals and anticoagulants. OWS did not test simple, affordable, available prevention strategies. Fortunately such RCTs where done outside of the US and have brought us important findings.

Balmforth et al, conducted a prospective double-blind, placebo-controlled trial of a xylitol based nasal spray in the prevention of SARS-CoV-2 infection in exposed healthcare workers in two hospitals in Uttar Pradesh, India. Xylitol is known to have anti-infective and anti-inflammatory properties and is used in XLEAR nasal spray and anti-infective chewing gum to prevent dental caries. Balmforth found that SARS-CoV-2 infection confirmed by serology was 71% lower with xylitol compared to placebo [36 cases (13.1%) Vs 97 cases (34.5%); odds ratio [OR] 0.29 (95% CI; 0.18–0.45), p < 0.0001]. Fewer clinical symptoms were also seen in the test group [57 cases (17.6%) vs 112 cases (34.6%); OR 0.40, (95% CI; 0.27–0.59), p < 0.0001]. No harmful effects were associated with xylitol. 

A smaller study of xylitol nasal spray in mild COVID-19 cases demonstrated that persistent loss of smell may be eliminated with xylitol nasal spray during the acute congestion phase.



Balmforth D, Swales JA, Silpa L, Dunton A, Davies KE, Davies SG, Kamath A, Gupta J, Gupta S, Masood MA, McKnight Á, Rees D, Russell AJ, Jaggi M, Uppal R. Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial. J Clin Virol. 2022 Oct;155:105248. doi: 10.1016/j.jcv.2022.105248. Epub 2022 Jul 25. PMID: 35952426; PMCID: PMC9313533.

I have been impressed with the RCTs of topical nasal sprays and gargles in COVID-19 far more than those with oral or intravenous drugs. Xylitol available as XLEAR in US pharmacies is one of several choices for local nasopharyngeal protection and treatment of COVID-19.

Sources and References:

Reposted from Peter A. McCullough’s Substack.

Related: Best Nasal Sprays for COVID-19

Comments

Post a Comment

Pages

Popular posts from this blog

Top Gold ETFs to Watch in 2025: Best Picks for Strong Returns and Low Costs

By -
Image
Top gold ETFs to watch in 2025 span U.S., Indian, Europe and Chinese markets, offering both physical gold exposure and mining stock leverage. Based on the latest performance, expense ratios, and trends, key ETFs include: SPDR Gold MiniShares Trust (GLDM) : The best-performing gold ETF by one-year return in 2025, up around 44%, with a very low expense ratio (0.10%). It tracks physical gold closely and is highly liquid, making it a top choice for cost-conscious investors seeking strong recent gains ( 2 ,  1 ). iShares Gold Trust Micro (IAUM) : Nearly matching GLDM’s performance with a 43.86% one-year gain and an even lower expense ratio (0.09%), this is an excellent low-cost option for gold exposure ( 2 ). abrdn Physical Gold Shares ETF (SGOL) : With about a 43.8% one-year return and expense ratio around 0.17%, this fund holds physical gold bullion and appeals to investors seeking stable, direct gold exposure ( 2 ,  1 ). GraniteShares Gold Trust (BAR) : Tracks physica...
Read more

AI in Algorithmic Trading & Investment Analysis (2025)

By -
Image
Executive Summary Algorithmic trading and investment analysis leverage advanced computer algorithms to automate and optimize trading decisions and portfolio management. Employing AI, machine learning, and real-time data, these systems enable faster, more accurate, and adaptive trading strategies that outperform traditional manual approaches. By 2025, algorithmic trading dominates global financial markets, with sophisticated AI models handling nearly 90% of trading volume (2), delivering significant competitive advantages, operational efficiency, and risk mitigation. This article discusses key trends and major related technologies shaping the current and near-future landscape of algorithmic trading and investment analysis. Introduction AI is fundamentally transforming algorithmic trading and investment analysis. By 2025, the fusion of advanced AI models, machine learning, and cloud platforms is making trading faster, more adaptive, and deeply data-driven for both institutional and retai...
Read more

Best Gold and Silver ETFs of 2025

By -
Image
Gold and silver ETFs are outperforming the S&P 500 index. But do these precious metals deserve a place in your investment portfolio? We provide a list of the best precious metals ETFs by 2025 performance, as well as the benefits and risks that investors need to know before buying these funds.  The best gold and silver ETFs of 2025 stand out due to exceptional performance, low expense ratios, and reliable tracking of precious metals’ prices. Here are the top options across global and key regional markets as of July 2025: Best Gold ETFs of 2025 SPDR Gold MiniShares Trust (GLDM) 1-Year Return: 43.90% Expense Ratio: 0.10% Notes: Best performing gold ETF, tracks physical gold, high liquidity, and cost-effective for retail investors ( 1 ,  2 ). iShares Gold Trust Micro (IAUM) 1-Year Return: 43.86% Expense Ratio: 0.09% Notes: Nearly matches GLDM in returns, with the lowest expense ratio among major gold ETFs ( 1 ). abrdn Physical Gold Shares ETF (S...
Read more

Top XRP ETFs to Watch in 2025: Dominating Holdings, Low Fees, and Performance Insights

By -
Image
As the cryptocurrency market matures in 2025, XRP ETFs have emerged as essential instruments for investors seeking regulated and accessible exposure to this dynamic digital asset. With a growing variety of futures-based and physically backed spot ETFs now available across major markets like the U.S., Canada, and Europe, understanding the nuances of these products—including their fee structures, holdings, and performance—is crucial for making informed investment decisions. This article highlights the top XRP ETFs to watch in 2025, providing deep insights into their dominating holdings, low fees, and recent market impact, all organized in a clear list format for easy navigation. Whether you are a long-term investor or an active trader, this guide will help you identify opportunities and risks in the evolving XRP ETF landscape. 1. Leading XRP ETFs in 2025 ProShares Ultra XRP ETF (UXRP) Type: 2x leveraged futures-based ETF listed in the U.S. Launched: July 18, 2025 Key Features...
Read more

We Asked Grok 3 to Predict the Market: Stocks, Bitcoin and More (July 2025 Edition)

By -
Image
Predicting what will happen in the markets is difficult, so we decided to see what AI had to say. We asked Grok 3 what July 2025 has in store for stocks, bitcoin, and more. Many try but few succeed in correctly predicting the markets — even among Wall Street analysts who do it for a living. Take the S&P 500, for example. The index closed 2024 at 5,882, cementing a second year of more than 20% gains. Yet at this time last year, Wall Street's 2024 median year-end price target was just 4,850, according to Bloomberg data. Not exactly close. Since experts are so often wrong, we figured it wouldn't be a bad idea to put Big Tech's trillion-dollar baby to work and ask AI for its predictions on the economy and markets going into 2025. Will Bitcoin or Nvidia go to the moon? Peak price prediction? We'll find out in next month... The S&P 500 will end the July 2025 month at 6,400. Grok 3 said:  My specific forecast, leaning toward a cautious but optimistic scenario, is 6,400...
Read more

Top 10 Most Anticipated Drug Launches of 2025

By -
Image
Biopharma may soon be in for a blockbuster boom. In the latest edition of its annual ranking of the biggest potential drug launches of the coming year, Evaluate listed 10 drugs that are slated to earn approvals in 2025. According to the analysts’ forecasts, all together, the meds stand to generate a whopping $29 billion in annual sales by the end of the decade. That’s nearly double the estimate for last year’s top 10 . In that case, Evaluate calculated a conservative $15.2 billion in 2028 sales for 2024’s biggest expected launches, which included the likes of Bristol Myers Squibb’s schizophrenia drug Cobenfy , Eli Lilly’s Alzheimer’s disease med Kisunla and Madrigal Pharmaceuticals’ MASH treatment Rezdiffra in the top three—all of which were indeed approved throughout last year. In fact, 2025’s total is the highest in the last five years, topping even Evaluate’s high-flying forecast for 2022, when the analysts estimated total 2026 sales of $26.9 billion for the year’s most anticipat...
Read more

Silicon Valley is foaming at the mouth with the promise of AI 'agents.' These are the startups to watch (2025)

By -
Image
Sam Altman, the CEO of OpenAI, has prophesied that this may be the year the first "agents" — a set of artificial intelligence tools that can perform tasks on their own — "join the workforce." Investors whose job it is to back new technologies before they become ubiquitous are swooning at the promise of these digital coworkers. The rise of agents offers fertile ground for a select group of startups to establish themselves as the front-runners of this shift. In that spirit, Business Insider reviewed press releases, news articles, and PitchBook data for startups exploring the application of agents across various sectors and then filtered for those companies that raised rounds of more than $25 million and less than $75 million in 2024. The result is a list of 20 startups that seem positioned to scale this year on the back of new funding. "If 2024 was the year of LLMs, we believe 2025 will be the year of agentic AI," said Praveen Akkiraju, a man...
Read more

Top 10 Pharmaceutical Companies by Revenue in 2025 (July Edition)

By -
Image
Here are the top 10 pharmaceutical companies by revenue as of 2025, primarily based on first quarter 2025 revenue data. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 ,  2 ,  3 ). In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). While earnings and revenue reports are considered lagging indicators that reflect past performance, the following articles offer a more forward-looking perspective, highlighting the potential future performance of related...
Read more

Top 10 Pharma Companies by Market Cap in 2025

By -
Image
Here are the top 10 pharmaceutical companies by market cap as of July 2025. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 ,  2 ,  3 ). In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Credit: CompaniesMarketCap.com Lilly—boosted by...
Read more

Did Steve Jobs Refuse Treatment for Pancreatic Cancer?

By Editorial Team -
Image
It’s been more than 12 years since the passing of Steve Jobs. Legendary Apple Inc., Co-founder Steve Jobs passed away at only 56 years old after battling pancreatic neuroendocrine tumor, a rare form of pancreatic cancer. A growing list of people in the public spotlight have faced pancreatic cancer, including tech innovators, entrepreneurs and influencers. In addition, and connected to Jobs, Jef Raskin, developer of the Macintosh computer, passed away of pancreatic cancer in 2005. And, coincidentally, Dag Kittlaus, creator of Siri, which was acquired by Apple in 2010, was diagnosed with the same exact cancer that took the life of Jobs. Pancreatic neuroendocrine tumors (or PNETs) account for less than 10% of all pancreatic cancer tumors and tend to grow slower than exocrine tumors, the most common type of pancreas tumors. Jobs survived eight years before dying of the disease on Oct. 5, 2011. The five-year survival rate for pancreatic cancer is only 10%. Since PNETs are so uncommon, trea...
Read more